Skip to main content
SpringerLink
Log in

Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

  • Viewpoint
  • Published:

From Nature Clinical Practice Cardiovascular Medicine

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Després JP and Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444: 881–887

    Article  Google Scholar 

  2. Hamdy O et al. (2006) Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2: 367–373

    Article  Google Scholar 

  3. Ritchie SA and Connell JM (2007) The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 17: 319–326

    Article  CAS  Google Scholar 

  4. Guilherme A et al. (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367–377

    Article  CAS  Google Scholar 

  5. Di Marzo V (2008) The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51: 1356–1367

    Article  CAS  Google Scholar 

  6. Matias I et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171–3180

    Article  CAS  Google Scholar 

  7. Pagano C et al. (2007) The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92: 4810–4819

    Article  CAS  Google Scholar 

  8. Blüher M et al. (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053–3060

    Article  Google Scholar 

  9. Côté M et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31: 692–699

    Article  Google Scholar 

  10. Aronne LJ and Isoldi KK (2007) Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. Am J Cardiol 100: 18P–26P

    Article  CAS  Google Scholar 

  11. Van Gaal L et al. (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 (Suppl 2): S229–S240

    Article  CAS  Google Scholar 

  12. Nissen SE et al. for the STRADIVARIUS Investigators (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299: 1547–1560

    Article  CAS  Google Scholar 

  13. Sanofi Aventis (online 5 May 2008) Imaging results from the ADAGIO-Lipids reveal that effects of rimonabant on cardiometabolic risk profile include loss of visceral fat and mobilization of liver fat. [http://www.sanofi-aventis.se/live/se/sv/layout.jsp?cnt=52DC240C-CD09- 4B62-87DC-C3FDD0B8AA43] (accessed 3 July 2008)

  14. Osei-Hyiaman D et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298–1305

    Article  CAS  Google Scholar 

  15. Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce. Nat Rev Drug Discov 7: 438–455

    Article  CAS  Google Scholar 

  16. Van Gaal LF et al. (2008) Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J [doi: 10.1093/eurheartj/ehn076]

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli (NA), Italy vdimarzo@icmib.na.cnr.it

Authors and Affiliations

  1. V Di Marzo is Research Director at the Italian National Research Council, Pozzuoli, Naples, Italy, and Coordinator of the Endocannabinoid Research Group in Naples.,

    Vincenzo Di Marzo

Authors
  1. Vincenzo Di Marzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

V Di Marzo has received research support and Speakers' Bureau honoraria from Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Marzo, V. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?. Nat Rev Cardiol 5, 610–612 (2008). https://doi.org/10.1038/ncpcardio1319

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1319

  • Springer Nature Limited

This article is cited by

Search

Navigation